AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta Q2 revenue falls 34% to $401.3 million; GAAP net loss of $4.9 million

Negative Impact 4 of 5 earnings Written later

Sarepta reported second quarter 2026 total revenues of $401.3 million, down 34% from $611.1 million a year earlier, and a GAAP net loss of $4.9 million, compared with GAAP net income of $196.9 million in the prior-year quarter. The company narrowed its 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, lowering the top of its prior $1.2 billion to $1.4 billion range, and new CEO Michael Severino took office July 28, 2026.

Key points

  • Q2 2026 total revenues were $401.3 million versus $611.1 million in Q2 2025; GAAP operating income was $13.3 million and non-GAAP operating income was $86.5 million.
  • GAAP diluted loss per share was $(0.05) for the quarter, compared with GAAP diluted earnings per share of $1.89 a year earlier.
  • FY 2026 total net product revenue guidance narrowed to $1.2 billion to $1.3 billion from $1.2 billion to $1.4 billion.
  • A $39.0 million litigation contingency charge was recorded related to potential resolution of certain patent litigations; cash and investments were $945.0 million as of June 30, 2026.

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:06 PM ET
Accession number0001193125-26-335056

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.